↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Three activists now control **24%** of Smith & Nephew, setting up credible push for portfolio split by mid-2025.
11%
in Smith &
157.4 million shares
worth approximately
$1.27 billion
at current trading levels
8.1%
and Polaris Capital Management's
Cevian Capital disclosed a stake above 11% in Smith & Nephew on Thursday, marking the third activist fund to take a material position in the London-listed medical device maker in the past eighteen months. The Stockholm-based firm now holds 157.4 million shares worth approximately $1.27 billion at current trading levels, sitting alongside Elliott Management's 8.1% and Polaris Capital Management's 5.3%. Combined, the three activists control over 24% of the company that has underperformed the MSCI World Healthcare Equipment Index by 37 percentage points since January 2020.
Smith & Nephew manufactures orthopedic reconstruction devices, advanced wound care products, and sports medicine equipment across 100 countries, generating $5.2 billion in trailing twelve-month revenue. The company has struggled with margin compression in its core knee and hip implant divisions, posting operating margins of 16.2% in the most recent quarter versus peer group averages near 23%. Management attributed the gap to integration costs from prior acquisitions and slower-than-expected adoption of its Cori robotic surgical platform, which has captured only 2.1% of the U.S. knee replacement market since its 2020 launch. Shares trade at 11.4x forward earnings, a 31% discount to Stryker and Zimmer Biomet.
Cevian's move above the 10% threshold triggers UK disclosure requirements and suggests the firm intends to coordinate with Elliott and Polaris rather than file independently. Elliott first disclosed its position in September 2023 and has since secured two board seats, including former Medtronic executive Gary Guthart. Polaris entered four months later with a public letter demanding portfolio rationalization and cost structure overhaul. The three funds share a common thesis: Smith & Nephew's diversified structure masks underperformance in each segment, and the company would generate higher returns as two separate entities—orthopedics and advanced wound management. Precedent exists. Zimmer Biomet spun off its spine division in 2021 and saw shares climb 48% in the following eighteen months. Johnson & Johnson separated its consumer health business in 2023 under similar activist pressure and now trades at a 19% premium to its pre-split multiple.
Operators should watch for a formal separation proposal at the company's February investor day, where management has promised to address capital allocation strategy. Elliott's board representatives are expected to present a detailed operational review comparing Smith & Nephew's segment-level returns against pure-play competitors. If the activists push for immediate action, expect a strategic review announcement by mid-March and formal spin documentation by June, assuming board alignment. Credit Suisse estimated a sum-of-the-parts valuation at $16.50 per share, 27% above current levels, with the orthopedics business likely commanding a 14-15x EBITDA multiple in a sale process.
Cevian typically holds positions for four to six years and has executed eleven successful operational turnarounds in European healthcare and industrials since 2015, including Bilfinger and Atos. The firm's entry at this stake size—above passive threshold, below control trigger—indicates confidence in a negotiated outcome rather than a proxy fight. Smith & Nephew's next earnings call is scheduled for February 20.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor February investor day for separation rhetoric; successful split historically adds 25-30% to comparable medtech positions within twelve months.
For the operator
Cevian's 11% cross signals coordinated push with Elliott; watch for strategic review by March and credit implications on orthopedics spinco debt capacity.
For the house
Long SNN March 15 calls, target $16; short comparable Stryker vol as reversion trade on healthcare equipment spread compression post-split announcement.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.